vimarsana.com

Page 7 - அல்லாத ஆல்கஹால் கொழுப்பு கல்லீரல் நோய் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Investegate |PureTech Health PLC Announcements | PureTech Health PLC: PureTech s Gelesis Presents Plenity Data at AACE

PureTech Founded Entity Gelesis Presents Findings on Plenity®-Induced Weight Loss at the American Association of Clinical Endocrinology (AACE) 2021 An

Search jobs 27-May-2021 PureTech Founded Entity Gelesis Presents Findings on Plenity®-Induced Weight Loss at the American Association of Clinical Endocrinology (AACE) 2021 Annual Virtual Meeting PureTech Founded Entity Gelesis Presents Findings on Plenity®-Induced Weight Loss at the American Association of Clinical Endocrinology (AACE) 2021 Annual Virtual Meeting Analysis showed that treatment for weight management with Plenity resulted in NALFD Fibrosis Score Improvement These data support further clinical investigation using Gelesis’ superabsorbent hydrogel platform for the potential treatment of metabolic-related liver disease First patient to enroll in a clinical trial leveraging this platform technology for treatment of NASH/NAFLD later this year

eureKARE launches with $60 million to build and finance next generation biotech companies in Europe

eureKARE launches with $60 million to build and finance next generation biotech companies in Europe B innovation eureKARE accompanied by a hig May 2021: eureKARE ( the Company ), a pioneering new company focused on financing and building next generation biotechnology companies in the disruptive fields of the microbiome and synthetic biology, today announces its launch with a $60 million Series A financing. The financing was supported by high-net worth investors and family offices. eureKARE is focused on two emerging and cutting-edge fields of research that have the potential to disrupt and revolutionize the life sciences industry: the microbiome and synthetic biology. Up to 90% of all diseases can be linked to the dysfunction and imbalance of the microbiome with the field forecast to reach $1.6 billion by 2028 at a CAGR of 21%. Synthetic biology, which comprises gene and cell therapy and industrial applications such as data storage and bioproduction, has seen huge advances

eureKARE launches with $60 million to build and finance next generation biotech companies in Europe

eureKARE launches with $60 million to build and finance next generation biotech companies in Europe
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.